Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XORTX Therapeutics Inc ( (TSE:XRTX) ) just unveiled an announcement.
On March 24, 2026, XORTX Therapeutics Inc. reported that shareholders approved a share consolidation at the company’s annual and special meeting, authorizing its board to implement a reverse split of up to five pre-consolidation common shares for each post-consolidation share. The move, which does not involve a name change and remains subject to TSX Venture Exchange approval, is intended to help the stock maintain compliance with Nasdaq’s minimum US$1.00 trading price and satisfy a condition that shares trade above that threshold for 10 days by April 13, 2026.
Before the consolidation, XORTX had 6,962,218 common shares outstanding, a figure expected to drop to roughly 1,392,443 post-consolidation, depending on the handling of fractional shares through cancellation or rounding. If the TSXV signs off, the stock will begin trading on a post-consolidation basis on a date to be announced, with registered shareholders required to exchange certificates while beneficial holders through brokers will see changes processed automatically, a step that could support the company’s continued access to U.S. capital markets and visibility among institutional investors.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company developing therapies targeting aberrant purine metabolism and xanthine oxidase to reduce uric acid production. Its lead programs include XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney and organ injury tied to respiratory virus infections, and the pre-clinical XRx-225 for Type 2 diabetic nephropathy.
The company focuses on improving outcomes for patients with gout and progressive kidney disease, positioning itself in a niche of renal and metabolic disorders. With three clinically advanced candidates and one pre-clinical program, XORTX aims to expand its presence in specialty therapeutics addressing significant unmet medical needs in kidney-related diseases.
Average Trading Volume: 5,476
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.46M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.